Dabigatran and Lapatinib Ditosylate

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Lapatinib may increase the blood levels and effects of dabigatran. Combining these medications may increase the risk of bleeding complications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Call your doctor promptly if you experience paleness of skin, fatigue, dizziness, fainting, unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, or weakness during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inhibitors of P-glycoprotein (P-gp) such as lapatinib may increase the plasma concentration of dabigatran etexilate, a substrate of the efflux transporter. When an oral dose of digoxin, a P-gp probe substrate, was administered with lapatinib, digoxin AUC increased up to 2.8-fold.

MANAGEMENT: Product labeling advises that use of dabigatran with P-gp inhibitors in patients with severe renal impairment (CrCl less than 30 mL/min) should be avoided. In patients taking dabigatran for the treatment or prophylaxis of deep venous thrombosis (DVT) or pulmonary embolism (PE), use of dabigatran with P-gp inhibitors in moderate renal impairment (CrCl 30 to 50 mL/min) should be avoided.

Dabigatran

Generic Name: dabigatran

Brand name: Pradaxa

Synonyms: Dabigatran Etexilate

What is Dabigatran?

Lapatinib Ditosylate

Generic Name: lapatinib

Brand name: Tykerb

Synonyms: Lapatinib

What is Lapatinib Ditosylate?